Equities Analysts Issue Forecasts for Collegium Pharmaceutical, Inc.’s Q2 2018 Earnings (COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Stock analysts at William Blair issued their Q2 2018 EPS estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Thursday. William Blair analyst T. Lugo anticipates that the specialty pharmaceutical company will earn ($0.38) per share for the quarter.

A number of other research firms also recently commented on COLL. Piper Jaffray Companies set a $14.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, July 25th. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $20.00.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Issue Forecasts for Collegium Pharmaceutical, Inc.’s Q2 2018 Earnings (COLL)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://stocknewstimes.com/2017/11/11/equities-analysts-issue-forecasts-for-collegium-pharmaceutical-inc-s-q2-2018-earnings-coll.html.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up $1.38 during trading hours on Friday, reaching $14.09. 2,270,000 shares of the company’s stock were exchanged, compared to its average volume of 829,686. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $18.02.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.13) earnings per share.

Several hedge funds have recently bought and sold shares of COLL. Nationwide Fund Advisors raised its holdings in shares of Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Collegium Pharmaceutical by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after buying an additional 3,775 shares during the period. American International Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Vanguard Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after buying an additional 58,398 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Collegium Pharmaceutical by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock valued at $1,474,000 after buying an additional 4,866 shares during the period. Hedge funds and other institutional investors own 83.25% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply